CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 144 enrolled
Drug / intervention
BNT162b1 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04523571
NCT04523571Phase 1Completed
CompareCT.gov

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study

BioNTech SE·interventional·Posted Aug 21, 2020·Updated Sep 18, 2023

In Brief

A Phase 1 clinical trial evaluating BNT162b1 and Placebo for SARS-CoV-2. Completed, enrolled 144 participants across 1 site.

Detailed Summary

This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesChina
CollaboratorsShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedAug 21, 2020
Enrollment StartJul 28, 2020
Primary CompletionSep 30, 2020
Study CompletionAug 10, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.9 years ago

Interventions

BNT162b1biological

Intramuscular injection

Placeboother

Intramuscular injection